A physician-scientist at the Korea Advanced Institute of Science and Technology (KAIST) has secured a 750 billion won (around 550 million USD) deal with a major global pharmaceutical company to develop and commercialize a new drug. The agreement ranks among the largest in Korean biotech history and reflects the country’s growing role as an innovator in the global pharmaceutical market. The clinician-researcher developed a promising therapeutic candidate aimed at a disease area with significant unmet medical needs. Although details about the drug remain confidential, its potential has drawn strong international interest. The partnership is expected to strengthen Korea’s biotechnology sector by attracting further investment, expanding collaboration with global pharma, and encouraging talent retention within the country. For KAIST, it also validates years of research focused on bridging laboratory discoveries with real-world medical applications. While the deal’s total value depends on meeting various development and sales milestones—a reminder of the risks inherent in drug development—it represents a landmark achievement that underscores Korea’s emergence as a serious player in cutting-edge medical innovation. (ICE SEOUL)

Fonte notizia: The Chosun Daily